Biogen Idec, Inc. (Massachusetts) No Longer for Sale; Shares Plunge

December 13, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Dec. 12 (Bloomberg) -- Biogen Idec Inc., the maker of the multiple sclerosis drug Tysabri, plunged 28 percent in extended New York trading after the biotechnology company said it didn't get any ``definitive'' takeover offers.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Mergers & acquisitions